Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease

Biotechnol Appl Biochem. 2001 Apr;33(2):85-9. doi: 10.1042/ba20000087.

Abstract

Human erythrocytes from ten patients with chronic obstructive pulmonary disease (COPD) were loaded with increasing amounts of dexamethasone 21-phosphate and were re-infused into the original donors. Drug-loaded erythrocytes acted as circulating bioreactors, converting the non-diffusible dexamethasone 21-phosphate into the diffusible dexamethasone. Pharmacokinetic analyses on these patients showed that a single administration of drug-loaded erythrocytes was able to maintain detectable dexamethasone concentrations in blood for up to seven days. This continuous release of dexamethasone was paralleled by the suspension of beta2-agonist and oral corticosteroid treatments by all of the patients. Thus dexamethasone 21-phosphate-loaded erythrocytes are safe carriers for corticosteroid analogues and are a useful alternative to frequent oral or inhaled drugs in elderly patients with COPD.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use
  • Chronic Disease
  • Dexamethasone / administration & dosage*
  • Dexamethasone / adverse effects
  • Dexamethasone / analogs & derivatives*
  • Dexamethasone / pharmacokinetics
  • Dexamethasone / therapeutic use
  • Drug Administration Schedule
  • Drug Carriers
  • Drug Delivery Systems / methods*
  • Erythrocytes*
  • Humans
  • Lung Diseases, Obstructive / drug therapy*
  • Middle Aged

Substances

  • Anti-Inflammatory Agents
  • Drug Carriers
  • dexamethasone 21-phosphate
  • Dexamethasone